Atopic Dermatitis Whole Blood
Fresh whole blood from IRB-consented donors with confirmed atopic dermatitis, a type 2 inflammatory skin disease driven by IL-4/IL-13 signalling and epidermal barrier dysfunction. Useful for IgE assay development, basophil activation testing, eosinophil immunophenotyping and biologic therapy response research.
Atopic Dermatitis Whole Blood for Allergy and Type 2 Inflammation Research
Atopic Dermatitis Whole Blood is collected from IRB-consented donors with a clinically confirmed atopic dermatitis diagnosis and shipped same day to preserve cellular and plasma analytes. Atopic dermatitis (eczema) is a chronic, relapsing inflammatory skin disease driven by type 2 immune activation together with epidermal barrier dysfunction. It is an allergic-type inflammatory condition rather than an autoimmune one, and these fresh samples support dermatology, allergy and biologic therapy research.
Type 2 Immune Activation and Barrier Dysfunction
- The dominant immune axis is type 2: IL-4 and IL-13 signalling drives class switching to IgE, eosinophil recruitment and the itch–scratch cycle, and blockade of this axis is the basis of current biologic therapy.
- IL-31 is a principal pruritogenic cytokine in atopic dermatitis and links type 2 inflammation directly to the itch that defines the patient experience.
- Epidermal barrier dysfunction is a co-primary mechanism. Loss-of-function variants in FLG, which encodes filaggrin, are the best-established genetic risk factor and permit increased allergen and irritant penetration.
- Total and allergen-specific IgE are commonly elevated, and peripheral blood eosinophil counts frequently track with disease activity — both accessible from whole blood.
- Atopic dermatitis is typically part of the broader atopic march, co-occurring with asthma, allergic rhinitis and food allergy, so atopic comorbidity metadata supports cross-condition research.
- Whole blood retains eosinophils, basophils, T cells and the IgE-containing plasma fraction in native proportions, allowing paired cellular and serological analysis from a single draw — something acellular matrices cannot provide.
Donor Stratification Available
- Disease severity as documented, including EASI or comparable severity scoring where available
- Total serum IgE level and peripheral eosinophil count where documented
- Atopic comorbidity: asthma, allergic rhinitis, food allergy, or skin-limited disease
- Treatment status: topical therapy only, dupilumab or other biologic, oral JAK inhibitor, systemic immunosuppressant, or treatment-naive
- Age of onset: paediatric-onset versus adult-onset disease
- Matched healthy controls available
Product Features
- Fresh whole blood from clinically diagnosed atopic dermatitis donors
- Custom anticoagulants and collection tubes available
- Same-day collection and shipment
- Custom volumes available on request
- Research Use Only (RUO)
De-identified Donor Data
- Physician-confirmed diagnosis, including EASI score and IgE levels where available
- Demographics: age, sex assigned at birth, ethnicity
- Relevant medical and treatment history
- Atopic comorbidities where reported
Applications
- Type 2 cytokine pathway research, including IL-4, IL-13 and IL-31 signalling
- Total and allergen-specific IgE assay development
- Basophil activation testing and allergen-stimulation assays
- Eosinophil and type 2 immune cell immunophenotyping
- Skin barrier and filaggrin genetic variant research
- Gene expression and transcriptomic analysis
- Biologic and JAK inhibitor therapy response research
- Whole blood stimulation and cytokine release assay development
Other Atopic Dermatitis Specimen Types
- Atopic Dermatitis Plasma
- Atopic Dermatitis Bulk Plasma
- Atopic Dermatitis Serum
- Atopic Dermatitis PBMC
- Atopic Dermatitis Leukopak
- Atopic Dermatitis Skin Punch Biopsy
Compliance and Quality Assurance
- IRB-approved protocols and electronic informed consent
- HIPAA-compliant donor data handling
Ordering & Customization
Atopic dermatitis whole blood is available in standard and custom volumes. For pricing, current availability, international orders or documentation requirements, email learnmore@sanguinebio.com. To browse donor cohorts across our full inventory, visit our human whole blood page.
Whole Blood
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Whole Blood cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.